Cover Image
市場調查報告書

葉酸受體α (成人葉酸結合蛋白質,葉酸受體1,KB細胞FBP,卵巢腫瘤相關抗原MOv18,FOLR1) :開發平台分析

Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361644
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
葉酸受體α (成人葉酸結合蛋白質,葉酸受體1,KB細胞FBP,卵巢腫瘤相關抗原MOv18,FOLR1) :開發平台分析 Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 44 Pages
簡介

本報告提供葉酸受體α (成人葉酸結合蛋白質、葉酸受體1、KB細胞FBP、卵巢腫瘤相關抗原MOv18、FOLR1)的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的評估

  • 單劑/聯合治療
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Advanced Accelerator Applications S.A.
  • Amgen Inc.
  • Nemucore Medical Innovations, Inc.
  • TapImmune Inc.

藥物簡介

暫停的計劃

最新消息和新聞稿

附錄

目錄
Product Code: GMDHC0076TDB

Summary

Global Markets Direct's, 'Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Pipeline Review, H1 2016', provides in depth analysis on Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1)
  • The report reviews Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) Overview
    • Therapeutics Development
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Products under Development by Stage of Development
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Products under Development by Therapy Area
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Products under Development by Indication
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Products under Development by Companies
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Companies Involved in Therapeutics Development
    • Advanced Accelerator Applications S.A.
    • Amgen Inc.
    • Nemucore Medical Innovations, Inc.
    • TapImmune Inc.
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Drug Profiles
    • FabOvar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMI-350 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONX-0801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Folate Receptor Alpha for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPIV-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Dormant Projects
    • Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) - Featured News & Press Releases
      • May 23, 2016: Nemucore Study Published in Molecular Pharmaceutics Furthers Understanding of NMI-350 and Theranostics for Ovarian Cancer
      • May 12, 2016: Nemucore Medical Innovations Announces NMI-350 ACOG Poster Presentation
      • Apr 21, 2016: TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
      • Apr 07, 2016: TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
      • Feb 03, 2016: Morphotek Announces Collaboration with Mayo Clinic to Apply its Folate Receptor Alpha Diagnostic Assays in A Phase II Clinical Trial in Triple-Negative Breast Cancer
      • Feb 03, 2016: TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
      • Dec 09, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to TapImmune's TPIV 200 in the Treatment of Ovarian Cancer
      • Sep 15, 2015: TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer
      • Jan 12, 2015: Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials
      • Sep 16, 2014: TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
      • Aug 07, 2014: TapImmune's New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens
      • Jul 25, 2011: VaxOnco To Sponsor Phase I Trial Of Folate Receptor Alpha-targeted Breast/Ovarian Cancer Therapeutic Vaccine
      • Sep 28, 2009: Onyx Pharmaceuticals Initiates Phase 1 Study of ONX 0801 in Advanced Solid Tumors
      • Aug 17, 2009: BTG Collaborator Onyx Gains Approval To Progress Oncology Compound Into Clinical Development
      • Nov 06, 2008: Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent from BTG International
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Advanced Accelerator Applications S.A., H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Nemucore Medical Innovations, Inc., H1 2016
  • Pipeline by TapImmune Inc., H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top